Arrowhead Pharmaceuticals/$ARWR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
Ticker
$ARWR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
609
ISIN
US04280A1007
Website
ARWR Metrics
BasicAdvanced
$2.3B
-
-$1.14
0.90
-
Price and volume
Market cap
$2.3B
Beta
0.9
52-week high
$30.41
52-week low
$9.57
Average daily volume
1.8M
Financial strength
Current ratio
0.845
Quick ratio
4.977
Long term debt to equity
91.52
Total debt to equity
91.52
Interest coverage (TTM)
-1.88%
Management effectiveness
Return on assets (TTM)
-5.86%
Return on equity (TTM)
-26.22%
Valuation
Price to revenue (TTM)
3.908
Price to book
3.4
Price to tangible book (TTM)
3.44
Price to free cash flow (TTM)
222.014
Growth
Revenue change (TTM)
1,436.97%
Earnings per share change (TTM)
-73.15%
3-year revenue growth (CAGR)
27.44%
3-year earnings per share growth (CAGR)
1.87%
What the Analysts think about ARWR
Analyst ratings (Buy, Hold, Sell) for Arrowhead Pharmaceuticals stock.
ARWR Financial Performance
Revenues and expenses
ARWR Earnings Performance
Company profitability
ARWR News
AllArticlesVideos
Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences
Business Wire·1 day ago
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call Transcript
Seeking Alpha·3 weeks ago
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arrowhead Pharmaceuticals stock?
Arrowhead Pharmaceuticals (ARWR) has a market cap of $2.3B as of May 30, 2025.
What is the P/E ratio for Arrowhead Pharmaceuticals stock?
The price to earnings (P/E) ratio for Arrowhead Pharmaceuticals (ARWR) stock is 0 as of May 30, 2025.
Does Arrowhead Pharmaceuticals stock pay dividends?
No, Arrowhead Pharmaceuticals (ARWR) stock does not pay dividends to its shareholders as of May 30, 2025.
When is the next Arrowhead Pharmaceuticals dividend payment date?
Arrowhead Pharmaceuticals (ARWR) stock does not pay dividends to its shareholders.
What is the beta indicator for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals (ARWR) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.